Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-21-Speech-2-525"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-21"^^xsd:date2
dcterms:Is Part Of	lp_eu:Pharmacovigilance of medicinal products (amendment of Regulation (EC) No 726/2004) - Pharmacovigilance (amendment of Directive 2001/83/EC) (debate)2
dcterms:Language	"pl"^^xsd:language2
lpv:document identification number	"en.20100921.18.2-525"2
lpv:hasSubsequent	lp_eu:2010-09-21-Speech-2-5272
lpv:speaker	lp:Bogusław Sonik2
lpv:spokenAs	member; EPP (2009-07-14--2014-06-30)3 member; Delegation for relations with Iran (2009-09-16--2014-06-30)3 unknown; Platforma Obywatelska (2009-07-14--2014-06-30)3 substitute; Delegation for relations with the countries of Central America (2009-09-16--2014-06-30)3 substitute; LIBE (2009-07-16--2012-01-18)3 vice-chair; ENVI (2009-07-16--2012-01-18)3 substitute; Delegation to the Euro-Latin American Parliamentary Assembly (2009-09-16--2014-06-30)3
lpv:translated text	"The statistics show that as many as half of patients do not take medicines in accordance with medical advice, and around three quarters of patients would like to have easy access to reliable information on the action of medicines and possible side effects. The proposal for supervision of the safety of medicines strengthens the safety of patients and guarantees them the right to better information about the uses and action of a particular medicine. An important step towards transparency of information about medicines is the project to open an Internet-based information service, both at European and national levels. The national websites will be connected with the European one and will have to contain a description of the characteristics of each product, an information leaflet and an evaluation of the product’s effect on human health. The European Medicines Agency, in cooperation with the Member States and the Commission, will supervise this database, where it will assemble and compare information as part of its work in pharmacological supervision. I think this is an important step towards ensuring patients the right to better, reliable and objective information about pharmaceutical products."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph